David Southwell named executive V.P. and CFO of Human Genome Sciences

David P. Southwell has been named executive vice president and chief financial officer of Human Genome Sciences, Inc.

Southwell will report directly to HGS president and chief executive officer H. Thomas Watkins and will serve as a member of the Management Committee of the company.

Southwell has previously served since July 2008 as a member of the HGS Board of Directors. He will resign his position on the board to accept this new position, which will become effective March 22.

"I am excited to be joining a team I know well from my role on the Board, at a pivotal time for the Company," Southwell said.

Prior to his joining the HGS board, Southwell worked at Sepracor, Inc., as executive vice president and chief financial officer.

"David Southwell brings more than twenty-five years of experience to HGS, including serving as Chief Financial Officer of a leading public specialty pharmaceutical company," Watkins said. "He has a significant track record of accomplishment in financial management and strategy. We are pleased to welcome David to his new role as we continue to move toward our goal of becoming a fully commercial biopharmaceutical company."

A graduate of Rice University, Southwell received his MBA from Dartmouth College's Tuck School of Business. He serves as chairman of the board of directors for BioSphere Medical, Inc., and is a member of the board of directors of PTC Therapeutics, Inc. He also serves as chairman of the Tuck School of Business MBA advisory board.